Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorbitol SCHEMBL619756 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL11015104 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28899433 | 0.95 | LMNA (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL27759 | 0.95 | LMNA (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL15060035 | 0.95 | LMNA (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Ribitol SCHEMBL3904172 | 0.94 | LMNA (0.53) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL20561020 | 0.94 | LMNA (0.53) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL4650185 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| E968 SCHEMBL578415 | 0.88 | ALDH1A1 (0.43) | LMNAL3MBTL1TDP1KDM4EUSP2 | |
| SCHEMBL15354798 | 0.87 | LMNA (0.52) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| CN-104418867-B | As the compound of PI3K/mTOR inhibitor, Preparation Method And The Use | 上海汇伦生命科技有限公司 | 2016-12-28 | — | — | CN | disclosed |
| CN-104557871-A | Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-104557955-A | Tricyclic compound as PI3K/mTOR inhibitor as well as preparation method and application of tricyclic compound | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-104557913-A | Pyridopyrimidine compounds as well as preparation method and application thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-104418867-A | Compound used as PI3K/mTOR inhibitor, preparation method and application | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2015-03-18 | — | — | CN | disclosed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | disclosed |
| WO-2009063644-A1 | EXTERNAL PREPARATION FOR THE SKIN | SHISEIDO COMPANY, LTD. (JP) | 2009-05-22 | — | — | WO | disclosed |
| EP-0092998-B1 | ETHERIFICATION PROCESS FOR HEXITOLS AND ANHYDROHEXITOLS | ICI AMERICAS INC. (US) | 1986-03-12 | — | — | EP | disclosed |
| US-4435586-A | POLYALKYLATION OF SORBITOL, SORBITAN, AND ISISORBIDE | ICI AMERICAS INC., A CORP. OF DE | 1984-03-06 | — | — | US | disclosed |
| EP-0092998-A1 | Etherification process for hexitols and anhydrohexitols | ICI AMERICAS INC. (US) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | MET, PDXK, FLT3 | LMNA 1971/4885L3MBTL1 4670/4885TDP1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.